

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 7630)

**POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY
GENERAL MEETING HELD ON JULY 27, 2026
AND
AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The board (the “**Board**”) of directors of IMPACT Therapeutics, Inc (the “**Company**”) announces that the 2026 first extraordinary general meeting of the Company (the “**EGM**”) was held at 10:00 a.m. on Monday, July 27, 2026 at Board Room, 27F, New Bund Times Square, 399 West Haiyang Rd., Pudong District, Shanghai, the PRC. References are made to the circular (the “**Circular**”) and the notice of the EGM of the Company both dated July 10, 2026. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular. The EGM was held in accordance with the requirements of the Listing Rules, the Company Law of the PRC and the Articles of Association.

POLL RESULTS OF THE EGM

The poll results of the EGM were as follows:

SPECIAL RESOLUTIONS		NUMBER OF VOTES (APPROXIMATE PERCENTAGE OF VOTES (%))		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the proposed adoption of the Share Award Scheme and the authorization to the Board to handle matters pertaining to the Share Award Scheme.	182,457,879 (98.486467%)	828,800 (0.447367%)	1,975,200 (1.066166%)
2.	To consider and approve the proposed amendments to the Articles of Association.	183,286,679 (98.933834%)	0 (0.000000%)	1,975,200 (1.066166%)

Note:

- (1) For details, please refer to the Circular.

As a majority of more than two-thirds of the votes were cast in favor of resolutions numbered 1 to 2 at the EGM, each of the aforesaid resolutions was duly passed as a special resolution.

- (2) As of the date of the EGM, the total number of Shares in issue was 282,461,530 H Shares, the holders of which were entitled to attend and vote on the resolutions at the EGM. There were no Shares entitling the holders to attend and abstain from voting in favour of any resolutions at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on any resolutions at the EGM. No Shareholder had stated his/her intention in the Circular to vote against or to abstain from voting on any resolutions at the EGM. Shareholders holding a total of 185,261,879 H Shares attended and voted at the EGM either in person or by proxy, representing approximately 65.59% of the Company's total Shares in issue.
- (3) The H Share registrar of the Company, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for vote-taking at the EGM.
- (4) The executive directors, Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA, non-executive directors, Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU, and independent non-executive directors, Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO attended the EGM either in person or by electronic means.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

As the special resolution in relation to the proposed amendments to the Articles of Association has been duly approved by the Shareholders at the EGM, the proposed amendments to the Articles of Association shall take effect on July 27, 2026. The amended Articles of Association will be published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.impacttherapeutics.com), respectively.

By order of the Board
IMPACT Therapeutics, Inc
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, July 27, 2026

As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive directors.